deltatrials
Recruiting PHASE3 INTERVENTIONAL 1-arm NCT04786262

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia

Sponsor: Vertex Pharmaceuticals Incorporated

Interventions VX-880
Updated 23 times since 2021 Last updated: Jul 29, 2025 Started: Mar 29, 2021 Primary completion: Jun 30, 2027 Completion: Jun 30, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04786262, this PHASE3 trial focuses on Diabetes Mellitus, Type 1 and Impaired Hypoglycemic Awareness and remains actively recruiting participants. Sponsored by Vertex Pharmaceuticals Incorporated, it has been updated 23 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Mar 2022 · 6 months · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~Jun 2023 · 3 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Jan 2025 · 2 months · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Apr 2025 · 59 days · monthly snapshot~Apr 2025 – ~Jun 2025 · 2 months · monthly snapshot~Jun 2025 – ~Aug 2025 · 2 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

23 versions recorded
  1. Sep 2025 — Present [monthly]

    Recruiting PHASE3

  2. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE3

  3. Jun 2025 — Aug 2025 [monthly]

    Recruiting PHASE3

  4. Apr 2025 — Jun 2025 [monthly]

    Recruiting PHASE3

  5. Feb 2025 — Apr 2025 [monthly]

    Recruiting PHASE3

Show 18 earlier versions
  1. Jan 2025 — Feb 2025 [monthly]

    Recruiting PHASE3

    Phase: PHASE1/PHASE2PHASE3

  2. Nov 2024 — Jan 2025 [monthly]

    Recruiting PHASE1/PHASE2

  3. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2PHASE1/PHASE2

  5. Nov 2023 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  6. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE1_PHASE2

  7. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE1_PHASE2

  8. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE1_PHASE2

  11. Mar 2023 — Jun 2023 [monthly]

    Recruiting PHASE1_PHASE2

  12. Sep 2022 — Mar 2023 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  14. Apr 2022 — Jun 2022 [monthly]

    Recruiting PHASE1_PHASE2

  15. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE1_PHASE2

  16. Sep 2021 — Mar 2022 [monthly]

    Recruiting PHASE1_PHASE2

  17. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  18. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Mar 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Vertex Pharmaceuticals Incorporated
Data source: Vertex Pharmaceuticals Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .